154 related articles for article (PubMed ID: 21171099)
1. Carbamylated erythropoietin does not alleviate signs of dystrophy in mdx mice.
Wu MP; Gussoni E
Muscle Nerve; 2011 Jan; 43(1):88-93. PubMed ID: 21171099
[TBL] [Abstract][Full Text] [Related]
2. Curcumin alleviates dystrophic muscle pathology in mdx mice.
Pan Y; Chen C; Shen Y; Zhu CH; Wang G; Wang XC; Chen HQ; Zhu MS
Mol Cells; 2008 Jun; 25(4):531-7. PubMed ID: 18460899
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
[TBL] [Abstract][Full Text] [Related]
4. Imatinib attenuates skeletal muscle dystrophy in mdx mice.
Huang P; Zhao XS; Fields M; Ransohoff RM; Zhou L
FASEB J; 2009 Aug; 23(8):2539-48. PubMed ID: 19289603
[TBL] [Abstract][Full Text] [Related]
5. Selective activation of α7 nicotinic acetylcholine receptor (nAChRα7) inhibits muscular degeneration in mdx dystrophic mice.
Leite PE; Gandía L; de Pascual R; Nanclares C; Colmena I; Santos WC; Lagrota-Candido J; Quirico-Santos T
Brain Res; 2014 Jul; 1573():27-36. PubMed ID: 24833065
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.
Cozzoli A; Rolland JF; Capogrosso RF; Sblendorio VT; Longo V; Simonetti S; Nico B; De Luca A
Neuropathol Appl Neurobiol; 2011 Apr; 37(3):243-56. PubMed ID: 20618838
[TBL] [Abstract][Full Text] [Related]
7. GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy.
Cozzoli A; Capogrosso RF; Sblendorio VT; Dinardo MM; Jagerschmidt C; Namour F; Camerino GM; De Luca A
Pharmacol Res; 2013 Jun; 72():9-24. PubMed ID: 23523664
[TBL] [Abstract][Full Text] [Related]
8. Nuclear magnetic resonance spectroscopy study of muscle growth, mdx dystrophy and glucocorticoid treatments: correlation with repair.
McIntosh L; Granberg KE; Brière KM; Anderson JE
NMR Biomed; 1998 Feb; 11(1):1-10. PubMed ID: 9608583
[TBL] [Abstract][Full Text] [Related]
9. Positive effects of bisphosphonates on bone and muscle in a mouse model of Duchenne muscular dystrophy.
Yoon SH; Sugamori KS; Grynpas MD; Mitchell J
Neuromuscul Disord; 2016 Jan; 26(1):73-84. PubMed ID: 26494410
[TBL] [Abstract][Full Text] [Related]
10. Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy.
Timpani CA; Goodman CA; Stathis CG; White JD; Mamchaoui K; Butler-Browne G; Gueven N; Hayes A; Rybalka E
Sci Rep; 2020 Jan; 10(1):1125. PubMed ID: 31980663
[TBL] [Abstract][Full Text] [Related]
11. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
[TBL] [Abstract][Full Text] [Related]
12. Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy.
Anderson JE; Weber M; Vargas C
Cell Transplant; 2000; 9(4):551-64. PubMed ID: 11038071
[TBL] [Abstract][Full Text] [Related]
13. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological control of cellular calcium handling in dystrophic skeletal muscle.
Ruegg UT; Nicolas-Métral V; Challet C; Bernard-Hélary K; Dorchies OM; Wagner S; Buetler TM
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S155-61. PubMed ID: 12206810
[TBL] [Abstract][Full Text] [Related]
15. L-arginine improves dystrophic phenotype in mdx mice.
Voisin V; Sébrié C; Matecki S; Yu H; Gillet B; Ramonatxo M; Israël M; De la Porte S
Neurobiol Dis; 2005 Oct; 20(1):123-30. PubMed ID: 16137573
[TBL] [Abstract][Full Text] [Related]
16. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
17. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.
Burkin DJ; Wallace GQ; Nicol KJ; Kaufman DJ; Kaufman SJ
J Cell Biol; 2001 Mar; 152(6):1207-18. PubMed ID: 11257121
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor type-β inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies.
Cofre C; Acuña MJ; Contreras O; Morales MG; Riquelme C; Cabello-Verrugio C; Brandan E
Biofactors; 2015; 41(2):111-20. PubMed ID: 25809912
[TBL] [Abstract][Full Text] [Related]
19. Myotonic ADR-MDX mutant mice show less severe muscular dystrophy than MDX mice.
Krämer R; Lochmüller H; Abicht A; Rüdel R; Brinkmeier H
Neuromuscul Disord; 1998 Dec; 8(8):542-50. PubMed ID: 10093060
[TBL] [Abstract][Full Text] [Related]
20. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.
Turgeman T; Hagai Y; Huebner K; Jassal DS; Anderson JE; Genin O; Nagler A; Halevy O; Pines M
Neuromuscul Disord; 2008 Nov; 18(11):857-68. PubMed ID: 18672370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
